Bevacizumab for Diabetic Macular Edema

Phase 2, randomised, single-blind trial of bevacizumab in diabetic macular edema (DME) (5 arms), sponsored by Jaeb Center for Health Research. Primary endpoints: Change in Central Subfield Retinal Thickness From Baseline Over All Study Visits at 12 weeks and Percentage of Participants With <250 Microns or ≥ 50% Reduction in Retinal Thickening From Baseline Over All Study Visits at 12 weeks. Started Jun 2006; status: completed.